Skip to content
Search

Latest Stories

Discrimination, poor mental health identified as key drivers of workforce attrition

Discrimination, poor mental health identified as key drivers of workforce attrition in UK healthcare
gettyimages

Implementing policies to combat discrimination could not only address inequity but improve workforce retention - suggests a new study

A nationwide survey has highlighted the significant impact of discrimination and poor mental health on the attrition of UK healthcare workers following the COVID-19 pandemic.

Published in The Lancet, the study found that healthcare staff experiencing higher levels of depression, anxiety, Post-Traumatic Stress Disorder (PTSD), and burnout were more likely to consider or act on leaving the National Health Service (NHS).


The findings are based on data from 3,282 healthcare workers surveyed in 2023–2024 as part of the UK-REACH (United Kingdom Research study into Ethnicity and COVID-19 outcomes in Healthcare workers) study.

Nearly half of respondents (1,414) reported having considered or taken steps toward leaving healthcare, with 6.5 per cent taking definitive action. Additionally, over 55 per cent of participants had contemplated or acted on changing their field.

Workers aged 50–<60, those from the Asian group, and in dental and nursing roles were found to be at higher risk of attrition.

The study also uncovered a link between poor mental health—specifically depression, anxiety, PTSD, and burnout—and intentions to leave healthcare.

Discrimination and harassment, whether from colleagues or patients, were strongly  associated with attrition intentions, as was feeling undervalued by the government.

“The profound association between poor mental health and intending to leave the NHS workforce suggests that effective mental health treatment for staff may improve retention alongside their health,” the authors stated.

They emphasised the need for fostering higher workplace engagement via supportive and collaborative environments, opportunities for personal development, and organisational changes to minimise burnout.

The study also called for policies to address workplace discrimination, noting that it “may not only help address inequity but improve retention.”

As healthcare demand grows, the NHS is projected to face a shortfall of over a quarter of a million staff by 2036/37.

To address the care backlog and workforce shortages, the government and the NHS have pledged to increase recruitment and also retain 130,000 staff by 2039.

“Retention is vital to address current staff shortages, avoid increasing pressure on remaining staff, and ensure sufficient capacity to train new staff,” the researchers noted.

They also suggested implementing measures to make staff feel valued by the government, including resolving pay disputes, to improve retention and sustain the healthcare workforce.

More For You

RPS backs Pharmacist Support "Gift in Wills" initiative

The ‘Gift in Wills’ initiative is delivered in partnership with Bequeathed.

Photo credit: gettyimages

Leave a legacy: RPS partners with Pharmacist Support to promote ‘Gift in Wills’

The Royal Pharmaceutical Society (RPS) has announced its support for the ‘Gift in Wills’ initiative run by Pharmacist Support, coinciding with the charity’s birthday celebrations today (Tuesday 15 April).

This collaboration allows RPS members to create a free will while also helping to safeguard the future of vital support services for the pharmacy profession.

Keep ReadingShow less
Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less